Management of Advanced Ovarian Cancer: Current Clinical Practice and Future Perspectives

Management of Advanced Ovarian Cancer: Current Clinical Practice and Future Perspectives

Ovarian cancer is the most lethal gynecologic malignancy, which causes 313,959 new cases and 207,252 deaths worldwide annually. The lack of specific symptoms, together with no effective screening tools, results in 75% of patients receiving their diagnosis at an advanced stage. The combination of cyt...

Full description

Saved in:

Bibliographic Details
Main Authors:	Dimitrios Papageorgiou, Galateia Liouta, Evangelia Pliakou, Eleftherios Zachariou, Ioakeim Sapantzoglou, Ioannis Prokopakis, Emmanuel N. Kontomanolis
Format:	Article
Language:	English
Published:	MDPI AG 2025-06-01
Series:	Biomedicines
Subjects:	advanced ovarian cancer cytoreductive surgery chemotherapy PARP inhibitors antibody-drug conjugates immunotherapy
Online Access:	https://www.mdpi.com/2227-9059/13/7/1525
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Opportunities for predictive proteogenomic biomarkers of drug treatment sensitivity in epithelial ovarian cancer
by: Trudy J. Philips, et al.
Published: (2025-01-01)

HER2-Positive Serous Endometrial Cancer Treatment: Current Clinical Practice and Future Directions
by: Dimitrios Papageorgiou, et al.
Published: (2024-12-01)

Therapeutic landscape of ovarian cancer: recent advances and emerging therapies
by: Ling Wang, et al.
Published: (2025-08-01)

Current Status and Controversies in Neoadjuvant Chemotherapy for Advanced Stage Ovarian Cancer: A Review
by: Jiaxi Li, et al.
Published: (2023-11-01)

Tubal Ectopic Pregnancy: From Diagnosis to Treatment
by: Dimitrios Papageorgiou, et al.
Published: (2025-06-01)

Optimizing the primary treatment of patients with advanced ovarian cancer
by: S. O. Nikogosyan, et al.
Published: (2016-11-01)

Imaging-based assessment of response to olaparib in platinum-sensitive relapsed ovarian cancer patients
by: Maria Delgado-Ortet, et al.
Published: (2025-06-01)

PARP Inhibitors in Ovarian Cancer: Resistance Mechanisms, Clinical Evidence, and Evolving Strategies
by: Shant Apelian, et al.
Published: (2025-05-01)

Clinical Outcomes of Poly(ADP–Ribose) Polymerase Inhibitors as Maintenance Therapy in Patients with Ovarian Cancer in the Southeastern Region of Korea
by: Hyeong In Ha, et al.
Published: (2024-10-01)

Recent Developments in Rare Ovarian Carcinosarcoma: Literature Review and Case Report
by: Alexandra Nienhaus, et al.
Published: (2025-05-01)

Proposed Nodal Cancer Index (NCI) in ovarian carcinomatosis
by: M D Ray, et al.
Published: (2025-04-01)

Advances in Cytoreductive Surgery and Combination Therapy for Ovarian Cancer
by: Xiaolan Lv, et al.
Published: (2022-07-01)

Systemic and tumor-specific inflammatory markers VCAM-1 and ICAM-1 as indicators of extent of surgery and oncologic outcome in advanced ovarian cancer
by: Okan Gultekin, et al.
Published: (2025-09-01)

A case report of long-term successful use of maintenance therapy with PARP inhibitors in the primary treatment of advanced BRCA-associated ovarian cancer
by: О. N. Churuksaeva, et al.
Published: (2023-09-01)

Comparative analysis of the diagnostyc value of CT and MRI in the assessment of peritoneal carcinomatosis in ovarian cancer
by: Yu. A. Soloveva, et al.
Published: (2025-03-01)

Neoadjuvant chemotherapy for advanced ovarian cancer: literature data and in vitro studies
by: S. A. Kuznetsov, et al.
Published: (2015-09-01)

Ovarian cancer: new accents treatment of patients with platinum-sensitive relapses
by: A. G. Kedrova, et al.
Published: (2016-11-01)

HELQ upregulates PARP1 to drive platinum resistance and predict therapeutic response in ovarian cancer
by: Shuran Tan, et al.
Published: (2025-07-01)

Use of individualized starting dose and niraparib hematologic adverse event management costs in ovarian cancer
by: Whitney S Graybill, et al.
Published: (2024-12-01)

Cost comparison of adverse event management among breast and ovarian cancer patients treated with poly (ADP-ribose) polymerase inhibitors: analysis based on phase 3 clinical trials
by: Lin Fan, et al.
Published: (2022-12-01)

Advances in Therapy for Urothelial and Non-Urothelial Subtype Histologies of Advanced Bladder Cancer: From Etiology to Current Development
by: Whi-An Kwon, et al.
Published: (2025-01-01)

High-Risk Factors and Therapeutic Advances in Ovarian Cancer
by: Xiaoyu SHA, et al.
Published: (2025-07-01)

Splenectomy during cytoreductive surgery in advanced epithelial ovarian cancer can be predicted
by: Thien-Kim Do, et al.
Published: (2025-06-01)

Personalised treatment of patients with advanced ovarian cancer: comparative analysis of surgical approaches
by: A. Rybin, et al.
Published: (2025-06-01)

CDC7 Inhibition Potentiates Antitumor Efficacy of PARP Inhibitor in Advanced Ovarian Cancer
by: Shini Liu, et al.
Published: (2024-12-01)

Primary versus interval debulking surgery in the management of ovarian cancer patients, current data summary
by: Victoria Psomiadou, et al.
Published: (2022-04-01)

Primary cytoreductive surgery followed by chemotherapy compared to neoadjuvant chemotherapy followed by cytoreduction as a treatment for stage III and IV ovarian cancer (literature review)
by: E. V. Sibirskaya, et al.
Published: (2024-05-01)

Cytoreductive HIPEC-Combined Surgery in Treatment of Advanced Ovarian Cancer
by: M. V. Zabelin, et al.
Published: (2022-06-01)

Optimal cytoreduction for advanced epithelial ovarian cancer
by: N. G. Kormosh, et al.
Published: (2014-08-01)

Placement of delayed absorbable mesh to prevent herniation following left diaphragm peritonectomy during ovarian cancer cytoreduction
by: Ryan M. Kahn, et al.
Published: (2025-04-01)

Challenges and opportunities to address the emerging burden of targeted therapies in ovarian cancer
by: Salamatu Abdul-Aziz, et al.
Published: (2025-02-01)

Determining the effect of frailty on survival in advanced ovarian cancer: study protocol for a prospective multicentre national cohort study (FOLERO)
by: Daniel Hunde, et al.
Published: (2025-02-01)

The role of Poly-ADP ribose polymerase (PARP) enzymes in chemotherapy-induced cognitive impairments – parallels with other neurodegenerative disorders
by: Dahlia A. Ordaz, et al.
Published: (2025-06-01)

Anesthesiological support of cytoreducative operations using hyperthermic intraperitoneal chemotherapy (hipec) in patients with ovaryan cancer
by: D. D. Morikov, et al.
Published: (2019-11-01)

Optimal cytoreductive surgery in patients with disseminated ovarian cancer (the department’s experience)
by: N. G. Kormosh, et al.
Published: (2014-07-01)

Exploring the radiochemistry of PARP inhibitors: a new era in therapy and imaging
by: Gianluca Destro, et al.
Published: (2025-07-01)

Emerging technology trends in regulatory approvals of cancer immunotherapy drugs by the FDA and EMA
by: Maryam Monajati, et al.
Published: (2024-09-01)

Research progress on ferroptosis and PARP inhibitors in ovarian cancer: action mechanisms and resistance mechanisms
by: Jiqing Zhang, et al.
Published: (2025-04-01)

Cytoreductive surgery with multimodal therapies in advanced or metastatic ovarian, colorectal, and gastric cancers: a systematic review and meta-analysis of randomized trials
by: Xiaojun Yuan, et al.
Published: (2025-07-01)

Multimodal data integration with machine learning for predicting PARP inhibitor efficacy and prognosis in ovarian cancer
by: Xi’an Xiong, et al.
Published: (2025-06-01)